latest update:
[TrialBase DB]

trial summary · NCT06319196

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High Risk Melanoma

Trial record from the TrialBase DB dataset, status RECRUITING, condition Cutaneous Melanoma, sponsored by University Health Network, Toronto. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06319196phase PHASE2enrollment 54start 2026-11-30

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Clear-Me is a biomarker-driven phase II study that tests whether the combination anti- lymphocyte-activation gene-3 (LAG3)/anti-programmed cell death protein 1(PD-1) inhibition Bristol-Myers Squibb (BMS986213) is superior to anti-PD-1 inhibition in patients with detectable circulating tumor deoxyribonucleic acid (ctDNA) following definitive surgery for high risk melanoma. Patients will be allocated to either Arm A or Arm B via the process of randomization. The randomization process will be stratified according to stage (Stage 2A/2B/3A/3B/3C/3D or 4), to ensure absolute balance between stage groups. The investigators are choosing only 1 stratification factor, disease stage, as the investigators consider stage being the most significant prognosticating variable. Each stage represents a biologically distinct entity with varying recurrence rate outcomes. Block randomization will be performed to ensure equal sample sizes in the combination and monotherapy arms. At least 54 patients will be included in the randomized part of the study. The investigators are expecting approximately 20% of the patients to have detectable ctDNA after definite surgery. Therefore, approximately 270 patients are expected to be enrolled and tested for ctDNA in the entire study.

Source record: https://clinicaltrials.gov/study/NCT06319196

Facts

registry idNCT06319196
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionCutaneous Melanoma
sponsorUniversity Health Network, Toronto
sponsor classOTHER
enrollment54
start date2026-11-30
primary completion2027-02-15
completion2030-02-15
results postednot reported

Conditions

  • Cutaneous Melanoma
  • Melanoma Stage IV
  • Mucosal Melanoma

Interventions

  • Opdualag
  • Nivolumab

Countries

  • Canada

Intervention types: DRUG

Work with this record